Amarin Corporation plc (NASDAQ: AMRN) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -0.96 | Insider Own | - | Shs Outstand | 20.68M | Perf Week | 0.70% |
| Market Cap | 297.00M | Forward P/E | - | EPS next Y | -0.06 | Insider Trans | 0.00% | Shs Float | 20.89M | Perf Month | -5.03% |
| Enterprise Value | 158.70M | PEG | - | EPS next Q | -0.02 | Inst Own | - | Short Float | 2.46% | Perf Quarter | -3.23% |
| Income | -26.94M | P/S | 1.60 | EPS this Y | 92.71% | Inst Trans | - | Short Ratio | 6.10 | Perf Half Y | 1.92% |
| Sales | 186.16M | P/B | 0.67 | EPS next Y | 14.29% | ROA | -4.34% | Short Interest | 513.20K | Perf YTD | 2.87% |
| Book/sh | - | P/C | 6.08 | EPS next 5Y | - | ROE | -5.99% | 52W High | 20.72 -31.29% | Perf Year | -4.58% |
| Cash/sh | - | P/FCF | 6.04 | EPS past 3/5Y | - | ROIC | -7.25% | 52W Low | 12.85 10.80% | Perf 3Y | -39.66% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | -16.61% -19.01% | Gross Margin | 41.58% | Volatility | 3.05% 3.40% | Perf 5Y | -82.66% |
| Dividend TTM | - | EV/Sales | 0.85 | EPS Y/Y TTM | 76.00% | Oper. Margin | -17.91% | ATR (14) | 0.52 | Perf 10Y | -69.96% |
| Dividend Ex-Date | - | Quick Ratio | 2.67 | Sales Y/Y TTM | -19.65% | Profit Margin | -14.57% | RSI (14) | 48.71 | Recom | 2.94 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.67 | EPS Q/Q | - | SMA20 | 1.84% | Beta | 0.74 | Target Price | 2.17 |
| Payout | 0.00% | Debt/Eq | 0.01 | Sales Q/Q | -42.47% | SMA50 | -2.95% | Rel Volume | 0.60 | Prev Close | 14.36 |
| Employees | 80 | LT Debt/Eq | 0.03 | Earnings | Nov 04 | SMA200 | -4.58% | Avg Volume | 72.73K | Price | 14.24 |
| IPO Date | Apr 01, 1993 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -100.00% -5.25% | Net Debt/EBITDA | 7.03 | Volume | 43,808 | Change | -0.84% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-25-23 | Downgrade | Jefferies | Buy → Hold | |
| Jan-06-23 | Upgrade | Jefferies | Hold → Buy | $3.00 |
| May-24-22 | Reiterated | Goldman Sachs | Sell | $1.50 |
| May-06-22 | Downgrade | JP Morgan | Neutral → Underweight | |
| May-05-22 | Downgrade | SVB Leerink | Outperform → Market Perform | |
| May-05-22 | Downgrade | HC Wainwright & Co. | Buy → Neutral | |
| May-05-22 | Reiterated | Northland Securities | $2.00 | |
| May-12-21 | Downgrade | Goldman Sachs | Neutral → Sell | |
| Mar-31-20 | Downgrade | Goldman Sachs | Buy → Neutral | |
| Mar-31-20 | Upgrade | Oppenheimer | Underperform → Perform |
Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the development and market introduction of drug products and new indications derived from Vascepa's active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 186 | 214 | 229 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 108 | 93 | 147 | — | — | — | — | — | — | |
| Gross Profit | 77 | 121 | 81 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 83 | 115 | 152 | — | — | — | — | — | — | |
| Research and Development | 19 | 20 | 21 | — | — | — | — | — | — | |
| Other Operating Expense | 9 | 0 | 0 | — | — | — | — | — | — | |
| Operating Income | -33 | -14 | -92 | — | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 7 | -22 | 15 | — | — | — | — | — | — | |
| Net Income Before Taxes | -26 | -36 | -77 | — | — | — | — | — | — | |
| Income Taxes | 2 | 3 | 5 | — | — | — | — | — | — | |
| Consolidated Net Income | -28 | -39 | -82 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -28 | -39 | -82 | — | — | — | — | — | — | |
| Net Income | -28 | -39 | -82 | — | — | — | — | — | — | |
| EPS (Recurring) | -1.43 | -1.80 | -4.00 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -1.43 | -1.80 | -4.00 | — | — | — | — | — | — | |
| EPS (Diluted) | -1.43 | -1.80 | -4.00 | — | — | — | — | — | — | |
| EBITDA | -19 | -33 | -74 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 1.61 | 1.37 | 0.89 | — | — | — | — | — | — | |
| Gross Margin | 41.40 | 56.54 | 35.37 | — | — | — | — | — | — | |
| Operating Margin | -17.74 | -6.54 | -40.17 | — | — | — | — | — | — | |
| Net Margin | -15.05 | -18.22 | -35.81 | — | — | — | — | — | — | |
| Shares Outstanding | 21 | 21 | 21 | — | — | — | — | — | — | |
| Market Capitalization | 299 | 293 | 204 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Fishman Peter L. | SVP, CFO | Aug 01 '26 | Option Exercise | 0.00 | 313 | 0 | 7,774 | Aug 03 |
| Ketchum Steven B | EVP, Chief Scientific Officer | Jul 01 '26 | Option Exercise | 0.00 | 3,688 | 0 | 44,567 | Jul 15 |
| Provoost Jonathan | EVP, Chief Legal Officer | Jul 01 '26 | Option Exercise | 0.00 | 3,688 | 0 | 5,888 | Jul 15 |
| Keenan David Paul | EVP, Chief Operating Officer | Jul 01 '26 | Option Exercise | 0.00 | 3,688 | 0 | 15,396 | Jul 15 |
| Fishman Peter L. | SVP, CFO | Jul 01 '26 | Option Exercise | 0.00 | 2,447 | 0 | 8,667 | Jul 15 |
| Berg Aaron | President and CEO | Jun 26 '26 | Option Exercise | 0.00 | 12,500 | 0 | 88,845 | Jun 30 |
| Bonfiglio Patrice Eadon | Director | Apr 18 '26 | Option Exercise | 0.00 | 1,676 | 0 | 1,239 | Apr 22 |
| Cohen Paul | Director | Apr 18 '26 | Option Exercise | 0.00 | 1,676 | 0 | 1,239 | Apr 21 |
| Sterling Louis III | Director | Apr 18 '26 | Option Exercise | 0.00 | 1,676 | 0 | 4,452 | Apr 21 |
| Odysseas Kostas D | Director | Apr 18 '26 | Option Exercise | 0.00 | 1,676 | 0 | 1,239 | Apr 21 |
| Sullivan Diane E. | Director | Apr 18 '26 | Option Exercise | 0.00 | 1,676 | 0 | 1,239 | Apr 21 |
| Horn Keith | Director | Apr 18 '26 | Option Exercise | 0.00 | 1,676 | 0 | 1,239 | Apr 21 |
| O'Connor Oliver | Director | Apr 18 '26 | Option Exercise | 0.00 | 1,676 | 0 | 1,239 | Apr 21 |
| Fishman Peter L. | SVP, CFO | Apr 01 '26 | Option Exercise | 0.00 | 250 | 0 | 6,282 | Apr 02 |
| Ketchum Steven B | EVP, Chief Scientific Officer | Jan 31 '26 | Option Exercise | 0.00 | 8,358 | 0 | 41,941 | Feb 03 |